company background image
ATRA

Atara BiotherapeuticsNasdaqGS:ATRA Stock Report

Market Cap

US$1.4b

7D

9.0%

1Y

37.8%

Updated

23 Sep, 2021

Data

Company Financials +
ATRA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ATRA Overview

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States.

Price History & Performance

Summary of all time highs, changes and price drops for Atara Biotherapeutics
Historical stock prices
Current Share PriceUS$17.30
52 Week HighUS$11.81
52 Week LowUS$28.20
Beta2.41
1 Month Change27.58%
3 Month Change5.81%
1 Year Change37.85%
3 Year Change-57.60%
5 Year Change-16.26%
Change since IPO44.17%

Recent News & Updates

Sep 20

Atara Biotherapeutics: One More Time

We take our second look at Atara Biotherapeutics and update our investment thesis to account for recent events. The company has a full slate of milestones over the next year including a rolling BLA submission. A full investment analysis and recommendation follows in the paragraphs below.

Aug 24
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Does the August share price for Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) reflect what it's really worth? Today, we...

Shareholder Returns

ATRAUS BiotechsUS Market
7D9.0%0.07%-0.5%
1Y37.8%31.0%37.5%

Return vs Industry: ATRA exceeded the US Biotechs industry which returned 28.4% over the past year.

Return vs Market: ATRA exceeded the US Market which returned 36.2% over the past year.

Price Volatility

Is ATRA's price volatile compared to industry and market?
ATRA volatility
ATRA Beta2.41
Industry Beta1.03
Market Beta1

Stable Share Price: ATRA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: ATRA's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012558Pascal Touchonhttps://www.atarabio.com

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis.

Atara Biotherapeutics Fundamentals Summary

How do Atara Biotherapeutics's earnings and revenue compare to its market cap?
ATRA fundamental statistics
Market CapUS$1.42b
Earnings (TTM)-US$317.78m
Revenue (TTM)US$7.42m

197.6x

P/S Ratio

-4.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ATRA income statement (TTM)
RevenueUS$7.42m
Cost of RevenueUS$13.32m
Gross Profit-US$5.89m
ExpensesUS$311.89m
Earnings-US$317.78m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-3.63
Gross Margin-79.40%
Net Profit Margin-4,281.64%
Debt/Equity Ratio0%

How did ATRA perform over the long term?

See historical performance and comparison

Valuation

Is Atara Biotherapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ATRA ($17.3) is trading below our estimate of fair value ($41.05)

Significantly Below Fair Value: ATRA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ATRA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ATRA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ATRA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ATRA is overvalued based on its PB Ratio (4.4x) compared to the US Biotechs industry average (3.2x).


Future Growth

How is Atara Biotherapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

37.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATRA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ATRA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ATRA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ATRA's revenue (69.3% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: ATRA's revenue (69.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ATRA is forecast to be unprofitable in 3 years.


Past Performance

How has Atara Biotherapeutics performed over the past 5 years?

-29.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ATRA is currently unprofitable.

Growing Profit Margin: ATRA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ATRA is unprofitable, and losses have increased over the past 5 years at a rate of 29.3% per year.

Accelerating Growth: Unable to compare ATRA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ATRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: ATRA has a negative Return on Equity (-95.85%), as it is currently unprofitable.


Financial Health

How is Atara Biotherapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ATRA's short term assets ($392.3M) exceed its short term liabilities ($88.8M).

Long Term Liabilities: ATRA's short term assets ($392.3M) exceed its long term liabilities ($36.4M).


Debt to Equity History and Analysis

Debt Level: ATRA is debt free.

Reducing Debt: ATRA had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ATRA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ATRA has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 27.8% each year.


Dividend

What is Atara Biotherapeutics's current dividend yield, its reliability and sustainability?

11.56%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ATRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ATRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ATRA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ATRA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ATRA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Pascal Touchon (58 yo)

2.25yrs

Tenure

US$5,285,827

Compensation

Dr. Pascal Touchon, D.V.M., has been President, Chief Executive Officer and Director at Atara Biotherapeutics, Inc. since June 24, 2019. He serves as Director of Cogen Therapeutics, Inc. since August 2018....


CEO Compensation Analysis

Compensation vs Market: Pascal's total compensation ($USD5.29M) is above average for companies of similar size in the US market ($USD3.68M).

Compensation vs Earnings: Pascal's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ATRA's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

Experienced Board: ATRA's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.1%.


Top Shareholders

Company Information

Atara Biotherapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Atara Biotherapeutics, Inc.
  • Ticker: ATRA
  • Exchange: NasdaqGS
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.423b
  • Shares outstanding: 84.76m
  • Website: https://www.atarabio.com

Number of Employees


Location

  • Atara Biotherapeutics, Inc.
  • 611 Gateway Boulevard
  • Suite 900
  • South San Francisco
  • California
  • 94080
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/23 23:07
End of Day Share Price2021/09/23 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.